[Lercanidipine in diabetic patients with renal failure].
Robles
N R
NR
Unidad de HTA, Hospital Infanta Cristina, Badajoz. nroblesp@meditex.es
Pastor
L
L
Manjón
M
M
Ocón
J
J
Gómez Campderá
F
F
Herrera
J
J
Villatoro
J
J
Calls
J
J
Torrijos
J
J
Rodríguez Villareal
I
I
Rodríguez Martínez
M A
MA
Méndez
M L
ML
Morey
A
A
Martínez Fernández
J
J
Marco
J
J
Liébana
A
A
Rincón
B
B
Tornero
F
F
D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D003404:Creatinine / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000150:complications*; D004095:Dihydropyridines / Q000009:adverse effects / Q000627:therapeutic use*; D004487:Edema / Q000139:chemically induced; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000188:drug therapy; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D003404:Creatinine; C060343:lercanidipine
Lercanidipino en pacientes diabéticos it con insuficiencia renal.